PFN2

Across TCGA pan-cancer cohorts, PFN2 mass-spec protein is linked to patient survival in 7 of 34 cancer types, making it a survival-associated PFN2 data layer compared with 25 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher PFN2 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated PFN2 expression acts as an unfavorable survival marker, although some lineages such as PDAC and LUAD show a favorable association.

CCRCC, HNSC, and GBM are the cancer types where PFN2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	OS	Tertile	All	0.728	0.994	<.001	83	view →
HNSC	DFS	Median	IV	0.328	0.889	.014	16	view →
GBM	OS	Tertile	All	0.290	0.615	.016	5	view →
UCEC	OS	Tertile	All	0.853	1.000	.015	4	view →
PDAC	OS	Tertile	IV	0.905	0.231	.024	3	view →
LSCC	OS	Quartile	III,IV	0.527	0.918	.034	2	view →
LUAD	DFS	Median	All	0.906	0.690	.044	1	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

PFN2–CCRCC (OS)

Open the CCRCC breakdown →